Drug Profile


Alternative Names: UTD-1

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Biostar Technologies
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 03 Apr 2017 Depoxythilone is still in phase III trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02253459)
  • 08 Aug 2014 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02253459; ChiCTR-TRC14005100)
  • 03 Jun 2014 Beijing Biostar completes phase II trials in Breast cancer (Late-stage disease, Combination therapy, Monotherapy, Metastatic disease) in China (IV) (ChiCTR-TRC-13004205)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top